FDA hits Cellectis’ off-the-shelf CAR-T program with clinical hold after first patient treated in phase 1 trial dies – FierceBiotech
FierceBiotech |
FDA hits Cellectis' off-the-shelf CAR–T program with clinical hold after first patient treated in phase 1 trial dies
FierceBiotech Doctors at the MD Anderson Cancer Center dosed the first blastic plasmacytoid dendritic cell neoplasm (BPDCN) patient with CD123-targeting CAR–T UCART123 on August 16. The patient died nine days later. Initially, the 78-year-old man responded to the … Patient Death Triggers FDA Hold For Cellectis's “Off the Shelf” CAR–T After Patient Death, FDA Places Clinical Hold on Cellectis CAR–T Candidate UCART123 Cellectis Reports Clinical Hold of UCART123 Studies |
